Items tagged with HIV coinfection

HIV virologic suppression maintained during latent TB treatment (post)

Virologic suppression can be maintained among patients with HIV infection receiving integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) in combination with short-course rifapentine-based regimens for latent tuberculosis (TB) management, according to study results published in Clinical Infectious Diseases.

ACTG announces launch of clinical trial evaluating drug-drug interaction in shortened TB regimen among people living with HIV (post)

LOS ANGELES, Feb. 14, 2024 -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 (Pharmacokinetics and Safety of Double-dose Dolutegravir When Used with Rifapentine for HIV-associated Tuberculosis). A5406 is a phase 2, open-label pharmacokinetic study investigating the effect that the anti-tuberculosis (TB) medication rifapentine has on levels of the HIV medication dolutegravir in the blood of participants who have HIV-associated TB and whether this combination can be safely and effectively used together.

Gilead press release: Biktarvy® demonstrates high rates of viral suppression in people with HIV and comorbidities (post)

March 06, 2024: Gilead Sciences, Inc. announced new data from three studies evaluating the efficacy and safety profile of Biktarvy^® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).

New study: Combo treatment can help solve the TB-HIV co-infection crisis - more than half a million people could benefit (post)

For people starting HIV treatment, combining dolutegravir-containing antiretroviral therapy with 3HP TB preventive treatment is safe and works effectively in tandem.

Comparative analysis of TB preventive therapy efficacies in HIV patients (post)

Latent Tuberculosis Infection (LTBI) is associated with increased immune activation and a heightened risk of cardiovascular diseases. The ACTG A5279 trial, a phase 3 study presented at the Conference on Retroviruses and Opportunistic Infections (CROI), investigated the activation patterns of monocytes in individuals with HIV (PWH). This trial compared the efficacy of 4 weeks of daily rifapentine (RFP) and isoniazid (INH) against 9 months of daily INH for Tuberculosis Preventive Therapy (TPT). At baseline and week 48, PWH with LTBI, compared to those with negative TST/IGRA results, demonstrated changes in monocytes indicative of ongoing activation and tissue migration.

Latest TB research publications (post)

TB CAB, TAG public comment in response to FDA guidance to TB drug developers (post with simple image)

Comment on Guidance for industry on pulmonary tuberculosis: Developing drugs for treatment.

SADC must unite to defeat scourge of TB: Motsoaledi (post with simple image)

Plans to implement screening programmes and regional treatment initiatives to combat tuberculosis with the same fervour as HIV/Aids are in the pipeline, Health Minister Aaron Motsoaledi said.

ERS/WHO TB Consilium on difficult-to-treat TB and TB/HIV cases (post with simple image)

If are you a physician dealing with complex M/XDR-TB, TB/HIV and other difficult-to-treat TB cases, the ERS/WHO TB Consilium can help you to manage them, free of charge.

India fights a tougher TB (post with simple image)

TB remains the deadliest infectious disease in the country with two deaths every three minutes.